High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma.
Journal
Cell proliferation
ISSN: 1365-2184
Titre abrégé: Cell Prolif
Pays: England
ID NLM: 9105195
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
03
05
2023
received:
18
03
2023
accepted:
16
05
2023
medline:
4
12
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
Having been reported to be a crucial prognostic factor in solid tumours, the role of high endothelial venule (HEV) in intrahepatic cholangiocarcinoma (ICC) remains unclear, however. The data of ICC and healthy individuals were downloaded from the Gene Expression Omnibus (GEO), and The Cancer Genome Atlas (TCGA) databases. Meanwhile, a cutting-edge ICC high-resolution spatial transcriptome was also acquired before these data were comprehensively analysed using bioinformatics approaches. Moreover, 95 individuals with ICC who had undergone resection surgery were enrolled in this study to investigate the relationship between HEV and tumour microenvironment (TME) applying immunohistochemistry and multiple immunofluorescence techniques. The high-HEV subtype contains rich immune infiltrates including tertiary lymphoid structure (TLS), CD8+ T cells, and CD20+ B cells. Furthermore, HEV and TLS exhibited a strong relationship of spatial colocalization. Correlated with improved prognostic outcomes in ICC, the high-HEV subtype could be an independent prognostic indicator for individuals with ICC. This study revealed the association of HEV with immune function and observed a strong spatial colocalization correlation between HEV and TLS. Moreover, correlated with immunotherapeutic response, HEV could improve prognostic outcomes, which may be a potential indicator of immunotherapy pathology in ICC.
Identifiants
pubmed: 37401015
doi: 10.1111/cpr.13513
pmc: PMC10693183
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13513Subventions
Organisme : Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
ID : 2022 LCYJ MS27
Organisme : Major Project of Nanjing Health Science and Technology Development
ID : ZDX22001
Organisme : Nanjing Municipal Administration of Health and Human Services
ID : YKK21074
Organisme : National Natural Science Foundation of China
ID : 82172631
Organisme : Research Project of Jinan Microecological Biomedicine Shandong Laboratory
ID : JNL202204A
Organisme : Research Project of Jinan Microecological Biomedicine Shandong Laboratory
ID : JNL202219B
Informations de copyright
© 2023 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.
Références
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S451-8
pubmed: 24633664
Oncoimmunology. 2015 May 7;4(6):e1008791
pubmed: 26155419
Nature. 2021 Aug;596(7871):211-220
pubmed: 34381231
Transl Gastroenterol Hepatol. 2018 Jul 12;3:40
pubmed: 30148225
J Transl Med. 2022 May 13;20(1):210
pubmed: 35562760
Nat Rev Immunol. 2004 May;4(5):360-70
pubmed: 15122201
Transl Oncol. 2019 Nov;12(11):1468-1479
pubmed: 31425839
World J Gastroenterol. 2009 Oct 28;15(40):5053-7
pubmed: 19859998
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Cancer Immunol Res. 2022 Jul 1;10(7):811-828
pubmed: 35604302
Cancer Res. 2011 Sep 1;71(17):5678-87
pubmed: 21846823
Histopathology. 2002 May;40(5):472-9
pubmed: 12010368
Nat Rev Immunol. 2003 Nov;3(11):867-78
pubmed: 14668803
Angiogenesis. 2021 Nov;24(4):719-753
pubmed: 33956259
J Clin Med. 2020 Aug 13;9(8):
pubmed: 32823631
Tumour Biol. 2016 Feb;37(2):2449-59
pubmed: 26383526
Hepatology. 2019 May;69(5):2091-2106
pubmed: 30615206
Front Immunol. 2021 Aug 30;12:705378
pubmed: 34526987
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Cell Prolif. 2023 Dec;56(12):e13513
pubmed: 37401015
J Immunol. 2018 Jan 15;200(2):432-442
pubmed: 29311385
Nat Commun. 2015 May 13;6:7114
pubmed: 25968334
Hepatol Res. 2020 Jan;50(1):84-91
pubmed: 31733634
Exp Mol Med. 2020 Sep;52(9):1475-1485
pubmed: 32913278
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
Annu Rev Immunol. 2004;22:129-56
pubmed: 15032576
Visc Med. 2016 Dec;32(6):427-430
pubmed: 28229078
Pathol Res Pract. 2021 Apr;220:153392
pubmed: 33647862
J Immunol. 2013 Aug 15;191(4):2001-8
pubmed: 23825314
Clin Transl Med. 2020 Jan;10(1):45-56
pubmed: 32508015
Am J Pathol. 2021 Feb;191(2):396-414
pubmed: 33159887
Cancer Immunol Res. 2022 Apr 1;10(4):468-481
pubmed: 35201289
Front Immunol. 2022 Apr 26;13:871769
pubmed: 35558087
Clin Cancer Res. 2020 Dec 1;26(23):6374-6386
pubmed: 32933997
Front Immunol. 2021 Aug 17;12:736670
pubmed: 34484246
Cancers (Basel). 2022 Apr 27;14(9):
pubmed: 35565318
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Front Immunol. 2016 Nov 09;7:491
pubmed: 27881983
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Biochim Biophys Acta Gene Regul Mech. 2023 Mar;1866(1):194889
pubmed: 36328277
Cancers (Basel). 2022 Aug 01;14(15):
pubmed: 35954412
Cancer Cell. 2022 Dec 12;40(12):1600-1618.e10
pubmed: 36423635
F1000Res. 2017 Feb 28;6:196
pubmed: 28344775
Clin Cancer Res. 2022 May 2;28(9):1896-1910
pubmed: 34526363
Hepatobiliary Surg Nutr. 2017 Feb;6(1):22-34
pubmed: 28261592
Immunol Today. 1995 Sep;16(9):449-57
pubmed: 7546210
Infect Immun. 2003 Jun;71(6):3572-7
pubmed: 12761142
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457
pubmed: 35365796
Cancer Immunol Res. 2017 Nov;5(11):1005-1015
pubmed: 28947544